Hyperthermia treatment planning including convective flow in cerebrospinal fluid for brain tumour hyperthermia treatment using a novel dedicated paediatric brain applicator by Schooneveldt, Gerben et al.
Hyperthermia treatment planning including convective flow in
cerebrospinal fluid for brain tumour hyperthermia treatment using
a novel dedicated paediatric brain applicator
Downloaded from: https://research.chalmers.se, 2020-01-17 15:55 UTC
Citation for the original published paper (version of record):
Schooneveldt, G., Dobsicek Trefna, H., Persson, M. et al (2019)
Hyperthermia treatment planning including convective flow in cerebrospinal fluid for brain
tumour hyperthermia treatment using a novel dedicated paediatric brain applicator
Cancers, 11(8)
http://dx.doi.org/10.3390/cancers11081183
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
cancers
Article
Hyperthermia Treatment Planning Including
Convective Flow in Cerebrospinal Fluid for Brain
Tumour Hyperthermia Treatment Using a Novel
Dedicated Paediatric Brain Applicator
Gerben Schooneveldt 1,*, Hana Dobšícek Trefná 2, Mikael Persson 2, Theo M. de Reijke 3,
Klas Blomgren 4,5 , H. Petra Kok 1 and Hans Crezee 1
1 Department of Radiotherapy, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam,
The Netherlands
2 Department of Electrical Engineering, Chalmers University of Technology, 41296 Gothenburg, Sweden
3 Department of Urology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
4 Department of Women’s and Children’s Health, Karolinska Institutet, 17164 Stockholm, Sweden
5 Department of Pediatric Oncology, Karolinska University Hospital, 17164 Stockholm, Sweden
* Correspondence: g.schooneveldt@amsterdamumc.nl
Received: 29 June 2019; Accepted: 13 August 2019; Published: 15 August 2019


Abstract: Hyperthermia therapy (40–44 ◦C) is a promising option to increase efficacy of radiotherapy/
chemotherapy for brain tumours, in particular paediatric brain tumours. The Chalmers Hyperthermia
Helmet is developed for this purpose. Hyperthermia treatment planning is required for treatment
optimisation, but current planning systems do not involve a physically correct model of cerebrospinal
fluid (CSF). This study investigates the necessity of fluid modelling for treatment planning.
We made treatments plans using the Helmet for both pre-operative and post-operative cases,
comparing temperature distributions predicted with three CSF models: a convective “fluid”
model, a non-convective “solid” CSF model, and CSF models with increased effective thermal
conductivity (“high-k”). Treatment plans were evaluated by T90, T50 and T10 target temperatures and
treatment-limiting hot spots. Adequate heating is possible with the helmet. In the pre-operative case,
treatment plan quality was comparable for all three models. In the post-operative case, the high-k
models were more accurate than the solid model. Predictions to within ±1 ◦C were obtained by a
10–20-fold increased effective thermal conductivity. Accurate modelling of the temperature in CSF
requires fluid dynamics, but modelling CSF as a solid with enhanced effective thermal conductivity
might be a practical alternative for a convective fluid model for many applications.
Keywords: hyperthermia treatment; treatment planning; computational fluid dynamics; cerebrospinal
fluid; brain malignancies; medulloblastoma
1. Introduction
Hyperthermia treatment, i.e., heating tumours to fever range temperatures (ca. 40–44 ◦C) for
a prolonged time (typically 1 h), has been proven to increase response rate and survival for a wide
range of tumours in patients treated with radiotherapy [1–4] or chemotherapy [5–7]. For example,
a randomized controlled trial comparing radiotherapy with and without hyperthermia in the treatment
of cervical cancer, showed a significantly improved 12-year local control (56% vs. 37%) and 12-year
overall survival (37% vs. 20%) in the hyperthermia arm [8]. Similarly, a randomized controlled trial
comparing chemotherapy with and without hyperthermia in the treatment of non-muscle invasive
bladder cancer, demonstrated that adding hyperthermia significantly improved 10-year disease free
survival from 15% to 53% [9].
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Brain tumours might particularly benefit from this synergistic treatment as radiotherapy leads to
severe late toxicities, especially in children [10]. The fact that brain tumours are relatively common in
children makes tackling this problem even more urgent. Moreover, many chemotherapeutic agents
do not adequately permeate through the blood brain barrier (BBB). Hyperthermia may mitigate
both problems. As one of the most potent radiosensitizers known, it allows for lower radiation
doses with equal treatment outcome, and no increased long term toxicities [11,12]. It has also been
known to temporarily open the BBB [13–15]. Kiyatkin et al. showed that the BBB in rats appears to
become permeable at 38.5 ◦C, reaching full permeability at 41 ◦C [16], suggesting that relatively mild
hyperthermia might suffice to enhance treatment efficacy. Another study reported that the BBB in rats
remains impermeable below 40.3 ◦C, but is fully permeable at 42.5 ◦C [17].
There are various types of malignant (primary) brain tumours, such as glioblastoma multiforme
(most common in adults) and medulloblastoma (most common in children). Clinical application of
hyperthermia for glioblastoma [18–21] has shown promising results; e.g., Sneed et al. [18] reported
a two-year survival rate of 31% in the arm with hyperthermia versus 15% in the arm without
hyperthermia. Byun et al. [22] reported, in a single-arm study in metastatic brain tumours, a 3-year
local recurrence rate of 15,8% after intra-operative hyperthermia, compared to 34% for a control group.
However, large-scale randomized controlled trials are lacking. Hyperthermia as an adjuvant treatment
for medulloblastoma has not yet been reported, but may similarly be expected to have a positive effect.
Nevertheless, heating the brain is not without difficulties. In general, the challenge is to get a sufficiently
high temperature in the tumour for a prolonged time, without excessive temperature increase in other
parts of the brain. As the brain is very sensitive to high temperatures [23,24], hyperthermia treatment
of the brain requires stricter temperature control than treatments in e.g., the pelvic area. In addition,
patients need to be awake and able to report neurological complaints related to excessive temperatures
in normal brain tissue.
There are several methods to raise the temperature in the brain, each with its own advantages
and drawbacks [25]. High-intensity focussed ultrasound (HIFU) can be an accurate treatment option
that may be combined with MR imaging (in particular MR thermometry), but the cranial bone often
makes HIFU delivery difficult or even impossible. Nevertheless, promising results have been shown
in mice and rats [26,27]. Non-thermal focussed ultrasound has been used in combination with
intravenously injected microbubbles to temporarily disrupt the BBB in a clinical feasibility study [28].
Magnetic nanoparticles are relatively easy to heat, but the temperature is difficult to control, and the
particles may cause severe artefacts in MR imaging, both for MR-based temperature control and
follow-up imaging [21]. Interstitial hyperthermia may obtain acceptable temperatures in the bulk
of the macroscopic tumour without creating unacceptable hot spots in healthy tissue, but may be
inadequate for heating the tumour infiltrations in surrounding normal brain tissue [19]. In practice,
the implantation of the required catheters is only justifiable when the patient also receives brachytherapy,
using the same catheters. Loco-regional microwave hyperthermia, on the other hand, should be able to
heat a larger portion of the brain, optionally including a margin around the tumour; such a margin
may be important because of diffuse infiltration (e.g., in the case of gliomas) or incomplete resection
(e.g., in the case of medulloblastomas, where about 50% of resections is incomplete [29]), and may
additionally result in better tumour coverage. Adequate power steering is important to avoid the risk
of causing hot spots in healthy tissue, potentially limiting overall treatment quality.
Although clinical application of hyperthermia for brain tumours has been limited to glioblastoma
multiforme, the most prevalent brain tumour in adults, many of the considerations (opening of the
BBB, radio-sensitisation, chemo-sensitisation) are equally valid for the treatment of medulloblastomas,
the most common brain tumour in children. Even low doses of ionizing radiation to the brain can
cause intellectual impairment [30–32] as well as perturbed growth [30,33] and puberty [34] and,
consequently, a radiosensitising treatment that may lead to lower radiation doses, is desired [10].
Adding hyperthermia may lead to the same effective dose with a lower physical dose, resulting in
fewer side effects [12,35].
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Despite these promising possibilities of adjuvant hyperthermia treatment for paediatric
medulloblastoma, current standard of care is limited to post-operative radiotherapy in combination with
chemotherapy, although also chemotherapy-related toxicity remains a major concern [36]. The absence
of trials investigating the benefit of adding hyperthermia in the treatment of paediatric medulloblastoma,
may be partly due to the technical challenges in administering adequate hyperthermia treatment in these
patients. In order to enable paediatric brain hyperthermia treatment, a microwave applicator, tentatively
dubbed the Chalmers Hyperthermia Helmet, was developed tailored for children, comprising up to
16 antennae operating at 430–900 MHz [37–40]. A schematic depiction of the second generation of
the Chalmers Hyperthermia Helmet is shown in Figure 1. The applicator comprises two arrays of
self-grounded bow-tie antennas [39] of two different dimensions and operated at 300–550 MHz and
430–900 MHz, respectively. Between the patient’s skin and the antennas, one or more water boli are
provided, to couple the electromagnetic field generated by the antennas into the patient and to cool the
patient’s skin. However, achieving a clinically acceptable temperature distribution may be challenging.
This is partly caused by the very high perfusion of the white and grey matter, quickly removing heat
and hence requiring relatively strong EM-fields; and partly by the presence of the cerebrospinal fluid
(CSF). Due to its high electric conductivity (σ > 2.0 S/m), the CSF absorbs EM radiation very efficiently
and is thus easily heated, quickly leading to treatment-limiting hot spots. Since the CSF is a fluid,
this heat can be transported over relatively large distances with the fluid flow. Therefore, CSF has a
significant influence on the temperature distribution in a large part of the brain.
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Figure 1. Model of the Chalmers Hyperthermia Helmet. Up to 16 self-grounded bowtie antennas
with a frequency range of 300–900 MHz are mounted around the skull. Phase and amplitude can be
optimised individually for each antenna, creating a power focus to be steered to the tumour. (a) Outside
view; (b) cross-section of a patient model, showing a large medulloblastoma in red and the water bolus
in light blue.
However, current hyperthermia treatment planning systems do not model fluid dynamics in a
physically correct manner, and do not take the effects of fluid flow into account, except, to some extent,
blood perfusion. Blood flow through small vessels (i.e., blood perfusion of various tissues) is typically
included with a greatly simplified model like Pennes’ bioheat equation [41], and some systems also
model individual large blood vessels using so-called discrete vasculature models [42,43]; however, the
effects of flow in larger contiguous fluid volumes are unaccounted for. Heat transport in such fluids
has two components: conductive (which is similar to solid tissues) and convective (which is associated
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with the bulk motion of the fluid). In body fluids with sufficient volume, such as blood in large blood
vessels, urine in the bladder, or CSF in the brain, convective heat transport is usually dominant.
For CSF specifically, heat is gained through direct absorption from the EM field and through
heat exchange with directly neighbouring tissues warmer than the CSF; and heat is lost through heat
exchange with tissues with a lower temperature, which in turn remove excess heat through heat
exchange with blood vessels. This results in temperature differences in the CSF, which give rise to
convective fluid flows, with a net effect of transporting heat upwards (against the direction of gravity).
Treatment planning systems that do not model fluid flow may, as a consequence, tend to overestimate
CSF-induced hot spots, and underestimate the heat distribution by the CSF.
Recently, we developed a thermodynamic fluid model as an extension to our existing treatment
planning system, Plan2Heat [44]. The direct motivation was to model the influence of urine, which
is also a relatively large contiguous fluid volume, on the temperature distribution in and around
the urinary bladder during pelvic hyperthermia treatments. This fluid dynamics modelling module
has been validated experimentally, showing an accuracy of ~0.1 ◦C [45–47], and has been applied
successfully for (retrospective) hyperthermia treatment evaluation of bladder cancer patients [48,49].
The aim of our current research is to assess the effect of CSF flow on the temperature distribution
in the human brain during microwave hyperthermia treatment using the Chalmers Hyperthermia
Helmet by numerical simulations including fluid dynamics modelling. Results are compared to those
obtained with standard solid models and will show whether fluid modelling is important for accurate
treatment planning.
2. Materials and Methods
2.1. Patient Model and Electromagnetic Field Simulations
An MRI scan with a 1 × 1 × 1 mm resolution was obtained from an actual patient, a 13-year old
boy with a large medulloblastoma (92 mL); in the context of the current proof-of-concept study, this
may be considered a valid model for various brain tumours. The scan was manually segmented by a
clinician into thirteen tissue types; the most relevant ones of which are tumour, tumour cyst, CSF, white
matter, grey matter, muscle, and bone. As can be seen in Figure 1b and Figure 10, only part of the head
was segmented. The section outside the treatment volume, i.e., the part of the head below the tumour
that is not covered by the applicator, was modelled as muscle. The tissue parameters used in the
simulations are based on literature values and are listed in Table 1 [50–53]. Normothermal perfusion
coefficients were used, except for muscle, for which a four-fold increased hyperthermic perfusion rate
of 3.6 kg/(m3 s) was used reflecting the enhanced muscle perfusion levels in response to hyperthermic
temperature elevations [53]. As in practice, hyperthermia treatments for medulloblastoma patients
would most likely be delivered post-operatively, we also created a ‘post-operative mesh’, in which the
tumour has been excised and the region was filled with CSF. This post-operative mesh was obtained by
labelling and treating all tumour and tumour cyst voxels as CSF. Although realistic deformations might
be less simplistic, this procedure provides a good test case for the purpose of this paper. All simulations
were performed for both the original, or ‘pre-operative’ mesh, and for the post-operative mesh.
A model of the Chalmers Hyperthermia Helmet comprising a water bolus at 10 ◦C and 14 antennas
operating at 450 MHz was created around the segmented head model [40,54]. The applicator comprises
two arrays of self-grounded bow-tie antennas [39] of two different dimensions and operated at
300–550 MHz and 430–900 MHz, respectively. The frequency considered in this study is thus a common
frequency for all fourteen antennas. For each antenna, the radiated electromagnetic field was computed,
with unit amplitude and zero phase, using CST Studio Suite (Dassault Systèmes, Vélizy-Villacoublay,
France). Subsequently, the amplitude and phase for each of the antennas were optimised to create a
power focus in the tumour region, using a time-reversal focusing method [55].
Cancers 2019, 11, 1183 5 of 23
Table 1. Dielectric and thermal parameter values at 450 MHz for the various tissue types used in
the simulations: electrical conductivity (σ [S/m]), relative permittivity (εr [-]), density (ρ [kg/m3]),
specific heat capacity (Ct [J/(kg K)]), thermal conductivity (k [W/(m K)]) and perfusion coefficient (ω Cb
[W/(m3 K)]), being the product of the volumetric perfusion rate (ω [kg/(m3 s)]) and the specific heat
capacity of blood (Cb = 3600 W/(m3 K). The last column indicates whether a tissue was modelled using
convective flow simulations (“yes”), or using Pennes’ equation (“no”). Parameters were obtained from
the IT’IS database [50], Gabriel and Gabriel [51], and Wang et al. [52]. The perfusion value of muscle
has been increased four-fold to account for vasodilation at hyperthermic temperatures, in accordance
with Kok et al. [53].
Tissue Type σ (S/m) εr (–) ρ (kg/m3) Ct (J/(kg K)) k (W/(m K)) ω Cb (W/(m3 K)) Flow
tumour 0.84 56.64 1056 3700 0.57 22,545 no
tumour cyst 0.84 56.64 1056 3700 0.57 0 no
cerebrospinal fluid 2.28 70.95 1007 4200 0.62 0 yes
grey matter 0.76 56.48 1038 3700 0.57 45,090 no
white matter 0.46 41.43 1038 3600 0.50 15,925 no
muscle 0.93 75 1050 3639 0.56 12,960 no
bone 0.095 13.03 1990 1300 0.40 3400 no
cartilage 0.60 44.94 1097 3500 0.47 9000 no
skin 0.71 45.70 1125 3500 0.42 8065 no
vitreous humour 1.54 69.00 1009 4200 0.60 0 no
air 0 1 1.293 10,000 0.024 0 no
bolus water 0.070 83.83 1000 4180 0.60 0 no
2.2. Temperature Simulations
The computation of the temperature distribution uses the same segmentation and is computed
based on this electromagnetic field distribution using a finite volume thermodynamic fluid model.
This model was built in OpenFOAM [56] and implements Pennes’ bioheat equation [41] in the solid
tissue regions, and uses the Boussinesq approximation to the Navier–Stokes equations for the fluid
(CSF) regions [57], which reads:
ρ
∂
→
v
∂t
+ ρ ∇ ·
(→
v
→
v
)
= µ ∇2→v −∇p+ ρk →g .
(
kg/
(
m2 s2
))
(1)
The left-hand side expresses the co-moving change over time t (s) to the velocity
→
v (m/s) of a fluid
element with (constant) mass density ρ (kg/m3). The right-hand side describes the forces acting on
the fluid element: the first term is the ‘friction’ between neighbouring fluid elements quantified by
the dynamic viscosity µ (Pa s), the second term is the spatial difference in pressure p (Pa). The third
term drives the convection and includes the gravitational acceleration
→
g (m/s) and the (non-constant)
kinematic density ρk (kg/m), which is assumed to depend linearly on the temperature. The equation
governing temperature change in the fluid compartment is:
Cp ρ
∂T
∂t
= k ∇2T −Cp ρ
(→
v · ∇T
)
+
1
2
σ E2,
(
W/m3
)
(2)
with Cp (J/(kg K)) the specific heat per mass, k (W/(m K)) the thermal conductivity, σ (S/m) the electric
conductivity, E (V/m) the electric field strength, and all other variables as in Equation (1). The reader is
referred to earlier publications for full details [46,48].
Meshes for thermal simulations in OpenFOAM were created and the resolution in the solid regions
was kept at 1 × 1 × 1 mm; in the fluid regions, these (1 mm)3 cubes were subdivided into six identical
pyramids by adding a vertex at the centre of the cube, in order to increase the computational stability.
For both the pre-operative case and the post-operative case, we evaluated three different models to
simulate the thermal behaviour of CSF:
1. fluid: the CSF was modelled using fluid dynamics, including convective flow;
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2. solid: the CSF was modelled as a solid, similar to current practice in available hyperthermia
treatment planning systems; and
3. high-k: the CSF was modelled as a solid with an n-fold increased thermal conductivity keff, with
keff/k = 2, 5, 10, 20, 50 and 100.
The comparison of these cases allows to evaluate the influence of fluid dynamics on the predicted
temperature distributions. Fluid dynamics modelling is relatively expensive in terms of computational
costs. The third case with enhanced effective thermal conductivity keff approximates the effect of
heat transport by fluid flow in a relatively simple and computationally efficient model, similar to
that described by Yuan et al. [58], allowing easy integration in a clinical workflow. The rationale for
introducing the concept of an enhanced effective thermal conductivity keff is that the most important
effect of fluid flow on the temperature distribution is more efficient heat transport. The main advantage
of this simplification is that the value of the thermal conductivity can be adjusted without any further
change to existing hyperthermia treatment planning software. Similar ideas, directed mostly to the
heat transport in blood vessels, have been reported in the literature [59,60]. The different values of keff/k
provide the possibility to study the effect of this increased effective thermal conductivity keff, and to
determine whether an appropriate value could approximate the advanced fluid dynamics model.
2.3. Analysis
The treatment plans, i.e., the set of phase and amplitude settings for each antenna, were obtained
by SAR-optimisation, but evaluated by the temperature distribution; consequently, the perceived
quality of a single SAR-based set of device settings, depends on the choice of the model used to
compute the temperature distribution. The treatment plans were analysed by determining the T90, T50
and T10 at steady state for the target volume, that is, the temperature exceeded by 90%, 50% and 10% of
the target volume, respectively. The target volume was split into the tumour and a 1 cm margin around
the tumour, which may cover regions of special interest, such as micrometastases or non-resectable
tumour residue. The tumour margin is analysed separately for solid tissues and CSF. For the grey and
white matter outside the tumour margin, we determined the V41, V42, and V43, defined as the volume
in which the temperature exceeds 41 ◦C, 42 ◦C and 43 ◦C, respectively. The same parameters were
determined for the CSF outside the tumour margin.
Hot spots were defined as regions with T > 44.0 ◦C within the macroscopic tumour including
tumour cysts, and as regions with T > 43 ◦C outside the macroscopic tumour [61,62]. The hot spots
were analysed by determining their cumulative volume for the CSF and the solid tissues separately
and together. We used the Dice coefficient [63] to quantify the amount of overlap between hot spots in
the fluid model on the one hand and in the solid and high-k models, respectively, on the other hand.
The Dice coefficient of two sets A and B is defined as 2 A∩B / (|A| + |B|), i.e., the intersection of the two
sets divided by the average size of the sets, which ranges from 0 for disjoint sets to 1 for identical sets.
In the second part of the analysis, we evaluated the difference between the simulation methods,
and determined the median error, interquartile range and 95%-interval of the error of the solid and
high-k methods relative to the fluid method. This part of the analysis shows how well each solid model
approximates the fluid model.
3. Results
The pre-operative mesh comprised 2.0 × 106 cells in the CSF region (340 mL) and 3.9 × 106 cells
for the solid regions; for the post-operative case, these numbers were 2.8 × 106 fluid cells (448 mL CSF)
and 3.7 × 106 cells for the solid regions. Typical computation times per second simulated time were
between 25 s and 97 s for the solid and high-k cases, and about 975 s and 1788 s for the pre-operative
and post-operative fluid cases, respectively, using a single core of a normal desktop personal computer
(Intel Xeon E5-1603 at 2.80 GHz processor, 16 GB RAM). Computation times may have been affected
by other processes running on the same computer, but are indicative of the very large difference in
computation time between the fluid model and the solid models.
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Figure 2 depicts the SAR distribution in the pre-operative and post-operative cases, while Figure 3
shows the resulting temperature distributions for the fluid, solid, and high-kmodels, and Figure 4 shows
the temperature differences between the fluid model and the solid and high-k models, respectively.
The high-k figures are for keff/k = 10.Cancers 2019, 11, x 7 of 24 
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We simulated the first 30 minutes (1800 s) of a treatment. While a typical hyperthermia treatment 
may last between 60 and 90 minutes, an equilibrium is reached long before then. The development 
over time of the T90, T50, and T10, shown for the pre-operative case in Figure 5 for (a) the tumour and 
(b) the CSF, confirms that an equilibrium is reached within these 1800 s. The cooling effect of the 
water bolus needs some time to penetrate into the body, which causes the delayed decrease of the T90 
in the CSF after an initial increase. The absence of such a delayed decrease in the tumour graph 
indicates that tumour temperature is not affected by the water bolus temperature. An analysis of the 
complete temperature distribution confirms that temperatures below 37 °C are only found in the 
outer 0.5–1.0 cm of the skull. 
  
Figure 4. Cont.
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confirms that an equilibrium is reached within these 1800 s. The cooling effect of the water bolus needs
some time to penetrate into the body, which causes the delayed decrease of the T90 in the CSF after an
initial increase. The absence of such a delayed decrease in the tumour graph indicates that tumour
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around the (former) tumour and is analysed separately as it is often a clinically relevant region: in 
the case of, e.g., glioblastoma, there are usually infiltrations or micrometastases in this region, while 
in the case of medulloblastoma, where micrometastases are not limited to a margin around the 
macroscopic tumour but may spread through the entire central nervous system, there are often non-
resectable tumour residues. Unless otherwise specified, the high-k models are represented by the keff/k 
= 10 model. 
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Figure 5. Development of T90, T50, and T10 over time for (a) the tumour and (b) the CSF (pre-operative
case) for the fluid model (blue), the solid model (green) and the high-k model (keff/k = 10) (red). Initially,
the graphs are virtually similar, but after a few minutes the fluid behaviour results in a different
temperature profile. While the temperature increase starts slowing down after about five minutes,
it takes about 25 min to reach the equilibrium situation. Figure (b) also shows the cooling effect of the
water bolus on the T90.
Figures 6–9 provide temperature results for the tumour including tumour cysts, respectively the
tumour region, the tumour margin, and the CSF. The tumour margin is defined as a 1 cm margin around
the (former) tumour and is analysed separately as it is often a clinically relevant region: in the case of,
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e.g., glioblastoma, there are usually infiltrations or micrometastases in this region, while in the case of
medulloblastoma, where micrometastases are not limited to a margin around the macroscopic tumour
but may spread through the entire central nervous system, there are often non-resectable tumour
residues. Unless otherwise specified, the high-k models are represented by the keff/k = 10 model.
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Figure 6. Temperature istograms showing volume quantile versus t mperature for (a,b)
the tumour (region), (c,d) the tumour margin (t mour margin), and (e,f) the grey/and white matter.
(a,c,e) In th pr -operativ case, these temp rature volume histograms are fa rly similar for the fluid,
solid, and igh-k models, although the solid and high-k models tend t ov restimate high temperature
volumes. (b,d,f) Post-operativel , the sit ti i i ilar for the white and grey matter, and more
pron unced for the tumour margin. For the CSF-filled volume where the tumour has been excised, the
differences are much larger. The fluid model reflects the efficient convective mixing leading to a relatively
homogeneous temperature in the fluid volume, the solid model has no way to efficiently dispose of the
generated heat and, therefore, greatly overestimates the temperature. The high-k models vary between
those two, and may overestimate heat removal for large values of keff/k, underestimating temperatures.
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Figure 6a–f show the temperature volume histograms, i.e., graphs depicting the quantile of
the volume heated to at least a given temperature, for the tumour, respectively or tumour region,
the tumour margin, and grey and white matter. For the pre-operative case, the graphs of the four
models are very similar: the main difference is that the fluid model shows fewer severe hot spots in the
tumour margin than the solid and keff/k = 10 models. Additionally, the keff/k = 100 model misses some
relatively mild hot spots. In the post-operative case, these differences are much more pronounced,
especially for the tumour region. Here, the fluid model shows a much more homogeneous profile
compared to the solid and keff/k = 10 models, due to the effective convective mixing in the fluid volume.
The high-k models are closer to the fluid model than the solid model, but still underestimate the mixing
effect, and, for larger keff, introduce a systematic cooling error.
Cancers 2019, 11, x 12 of 24 
 
 
 
 
pre-operative case 
 
(a) 
 
 
 
(b) 
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the treatment target, a temperature in the range 42–43 °C is clinically considered optimal. (b) shows 
for the healthy tissue the volume exceeding, respectively, 41, 42 and 43 °C (a darker shade 
representing a higher temperature). Clinically, these volumes should be as low as possible. Total 
volume: white matter = 125 mL; grey matter = 1007 mL; CSF = 340 mL; tumour = 92 mL. The exact 
numbers are provided in Table S1. 
 
Figure 7. Analysis of treatment plan parameters for the post-operative case. (a) shows the temperature
distribution in he treatm n target: box: inter-quartile e ith median temperature T50 in icated;
whiskers: T90 and T10, i.e., the tempe re excee ed by, r spectively, 90% and 10% of the volume.
For the treatment target, a temperature in the range 42–43 ◦C is clinically considered optimal. (b) shows
for the healthy tissue the volume exceeding, respectively, 41, 42 and 43 ◦C (a darker shade representing
a higher temperature). Clinically, these volumes should be as low as possible. Total volume: white
matter = 125 mL; grey matter = 1007 mL; CSF = 340 mL; tumour = 92 mL. The exact numbers are
provided in Table S1.
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Figure 8. Analysis of treatment plan parameters for the pre-operative case. (a) shows the temperature
distribution in the treatment target: box: inter-quartile range with median temperature T50 indicated;
whiskers: T90 and T10, i.e., the temperature exceeded by, respectively, 90% and 10% of the volume. For
the treatment target, a temperature in the range 42–43 ◦C is clinically considered optimal. (b) shows for
the healthy tissue the volume exceeding, respectively, 41, 42, and 43 ◦C (a darker shade representing
a higher temperature). Clinically, these volumes should be as low as possible. Total volume: white
matter = 125 mL; grey matter = 1007 mL; CSF = 448 mL. The exact numbers are provided in Table S2.
The main thermal parameters for evaluation of the treatment plan are summarised in Figure 7
and Table S1 for the pre-operativ ca e and in Figure 8 and Table S2 for the po t-operative case. For the
pre-oper tive case, T90 and T50 in the tumour and in the solid tissues in the tumour margin may
be considered equivalent, as they differ at most 0.1 ◦C As T90 and T50 are most indicative of clin cal
effect, all three simulation methods predict a comparable efficacy of this treatment plan; i.e., of the
given set of phase and amplitude settings for the antennas. All three methods predict a hot spot in
the tumour, although they differ in the severity (45.8 ◦C for the fluid model, 46.4 ◦C for the high-k
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model, and 46.8 ◦C for the solid model). The most pronounced differences are for the T10 in the CSF
surrounding the tumour: a moderate 44.7 ◦C hot spot for the fluid model, versus a 46.3 ◦C hot spot for
the high-k model and an even higher 48.8 ◦C for the solid model. In the grey and white matter analysis,
the results are qualitatively the same for all models, with the exception of the CSF outside the tumour
margin, where the solid model predicts 10.8 mL of CSF ≥ 43 ◦C, compared to only 1.8 mL for the fluid
model and 1.2 mL for the high-k model.
In the pre-operative case, the solid model predicts considerably more and larger hot spots in
the solid tissue outside the tumour than the fluid model (Dice coefficient 0.68); while even the best
performing high-k model (keff/k = 20) misses the smaller hot spots predicted by the fluid model, and
overestimates the size of the hot spot between the tumour and the back of the skull (Dice coefficient
0.77). As keff increases, the amount of incorrectly predicted hot spots (false positives) reduces, while the
missed hot spots (false negatives) increase in volume. The hot spots in the CSF are again overestimated
by the solid model, but increasingly missed with increasing keff, so that the keff/k = 2 model actually
performs best with regards to hot spots in the CSF (Dice coefficient 0.67). A full overview of the hot
spot volumes and Dice coefficients is given in Table 2.
Table 2. Hot spot volume and overlap as predicted by the various models and cases are shown. For
the pre-operative case, the volume of the hot spots (in mL) in healthy tissue is given, the overlap with
the volume according to the convective fluid model, and the Dice coefficient of the overlap; this is
done separately for the solid tissues (except tumour and tumour cyst), the CSF, and the combination.
The model having the highest Dice coefficient is rendered in boldface. For the post-operative case, only
the volumes (in mL) are given, as the convective fluid model predicts hardly any hot spots and all Dice
coefficients are <0.1.
Case Region Parameter Fluid Solid 2 k 5 k 10 k 20 k 50 k 100 k
pre-op
solid
volume 22.31 36.46 30.45 24.84 22.29 20.55 17.43 14.26
overlap 22.31 20.00 19.29 17.71 16.88 16.42 15.11 13.14
Dice 1.00 0.68 0.73 0.75 0.76 0.77 0.76 0.72
CSF
volume 23.94 29.37 21.39 16.12 13.20 12.61 12.57 11.68
overlap 23.94 17.08 15.15 12.69 11.30 11.56 11.62 10.78
Dice 1.00 0.64 0.67 0.63 0.61 0.63 0.64 0.61
total
volume 46.25 65.83 51.85 40.96 35.49 33.17 29.99 25.94
overlap 46.25 37.08 34.45 30.40 28.18 27.99 26.73 23.91
Dice 1.00 0.66 0.70 0.70 0.69 0.70 0.70 0.66
post-op
solid volume 0.23 19.76 17.37 14.33 10.59 5.60 0.64 0
CSF volume 2.74 125.11 120.91 112.89 103.80 84.28 24.95 0
total volume 2.97 144.87 138.27 127.22 114.38 89.88 25.59 0
In the post-operative case, the differences in the treatment plan analysis are larger than in the
pre-operative case. The most notable difference is found in the T10 (i.e., highest temperatures) for the
target regions and the T50 for the circumtumoral CSF. In particular, the solid model predicts a T50 of
52.2 ◦C for the circumtumoral CSF, compared to an almost acceptable 44.2 ◦C for the keff/k = 10 model
and a safe and desirable 42.5 ◦C for the fluid model. The T90 for the solid tumour margin is predicted
as 40.9 ◦C by the fluid model, 42.3 ◦C by the keff/k = 10 model, and 44.2 ◦C by the solid model.
The fluid model predicts almost no hot spots in the post-operative case, while the solid model
predicts a large hot spot in the former tumour region, and small hot spots immediately around it.
As keff increases, the hot spots inside and surrounding the CSF decrease, until they disappear for
keff/k ≥ 50. As the reference hot spot volume is practically zero, the Dice coefficients are all < 0.1 for the
post-operative case and not included in Table 2.
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the CSF (c,d) and the tumour (e) as predicted by the fluid model and the solid model (keff/k = 1) and 
the high-k models for the pre-operative, respectively the post-operative case. A high-k model with 
higher keff tends to slightly underestimate the temperature, but has smaller error bars. Horizontal axis: 
keff/k, vertical axis temperature in °C. 
Figures 9a–e summarise the difference of the solid and high-k models with the fluid model for 
the pre-operative and post-operative cases, respectively, in a set of box whisker plots showing the 
median, interquartile range, and 95%-interval. For the pre-operative case, the median temperature 
Figure 9. Box whisker plots of the te perature differences for the solid regions except tumour (a,b),
the CSF (c,d) and the tumour (e) as predicted by the fluid model and the solid model (keff/k = 1) and the
high-k models for the pre-o erative, respectively the post-operative case. A high-k model with higher
keff tends to slightly underestimate the temperatur , b t has smaller error bars. Horizontal axis: keff/k,
vertical axis temperature in ◦C.
Figure 9a–e sum arise the difference of t li high-k models with the fluid model for
the pre-operative and post-oper s, respectively, in a set of box whisker plots showing the
median, interquartile range, and 95 l. For the pre-operative case, the median temperature
difference and interquartile range are all well within ±0.1 ◦C. However, the solid model temperature
error for the healthy tissues has a larger spread than the high-k models: the 95% interval decreases from
(−0.8 ◦C, +0.9 ◦C) for the solid model to ±0.6 ◦C for keff/k = 50. This implies that the high-k models give
a better approximation to the fluid dynamics (with, in this case, an optimum for keff/k = 50), but may
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still be insufficiently precise for many applications. For the grey and white matter, a similar pattern
emerges, but with generally smaller inaccuracies. For the temperature of the CSF, both outside the
target region, and in particular inside the target region, the predictions by the solid and model are
even less reliable; for example, the 2.5th and 97.5th percentile of the temperature difference for the
CSF in the target region are −3.85 ◦C and 9.05 ◦C, respectively; these values move towards zero for
increasing keff, and are −3.34 ◦C and 1.37 ◦C for the keff/k = 100 model. The CSF temperature, both
inside and outside the target region, is generally underestimated for higher keff, with the interquartile
range between roughly −1 ◦C and 0 ◦C.
For the post-operative case, the results are essentially similar, but magnified. The largest
temperature deviations are, unsurprisingly, obtained for the solid model in the CSF-filled (former)
tumour region, where the mean± SD temperature difference is 10.6± 7.7 ◦C and the median temperature
difference is 9.8 ◦C. For the keff/k = 10 model, these numbers have shrunk to 1.8 ± 1.9 ◦C and 1.8 ◦C,
respectively. For the grey and white matter, the difference between the solid and high-k models on the
one hand and the fluid model on the other, are much smaller. The mean and median differences are all
smaller than 0.1 ◦C, and the standard deviation varies from 0.2 ◦C (white matter, keff/k = 10 model) to
0.6 ◦C (grey matter, solid model).
In general, a higher keff leads to a lower estimated temperature in the CSF, which may easily lead
to an underestimation of the fluid temperature. This is seen in both the pre-operative (Figure 9c) and
post-operative (Figure 9d) cases, where the median temperature difference decreased from +0.1 ◦C
for the solid model to −0.5 ◦C for keff/k ≥ 20. At the same time, the range of the errors decreases, and
seems to reach a plateau for keff/k ≥ 50.
Figure 10 shows the direction and velocity of the flow in the CSF in the post-operative case.Cancers 2019, 11, x 17 of 24 
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colour bar. The solid tissues are colour-coded according to tissue type, using the same colour map as
Figure 1b. The panels show planes through the tumour’s centre of gravity in the left-right (top-left),
anterior-posterior (top-right), and cranial-caudal (bottom-left) directions.
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4. Discussion
This study evaluated the importance of fluid dynamics modelling for treatment planning of
local/loco-regional microwave hyperthermia treatments of brain tumours. As long as there are no large
contiguous fluid volumes, CSF flow has a mostly minor influence on the temperature distribution in
the human brain during microwave hyperthermia treatment. The differences are most noticeable in
the CSF itself, and almost negligible in the tumour. For the pre-operative case, the differences in plan
evaluation parameters between the three models are small (Figure 7 or Table S2), although locally the
predicted temperature differences may be several degrees (Figure 9). These large differences appear
mostly in regions where the temperatures are not very high, such as the CSF layer directly beneath the
skull, which is not relevant as a treatment target and where, due to the vigorous surface cooling, there
is no substantial danger for hot spots. The cooling effect of the water boli at 10 ◦C penetrates about 1 cm
into the skull, which may be sufficient in some places to reach a CSF region. In such places, the CSF
may spread the cooling effect over a larger volume. The models with increased effective conductivity
substantially consistently perform better than the solid model with unadjusted thermal conductivity in
the CSF.
For the post-operative case, which for medulloblastoma will be the most likely clinical application,
the evaluation parameters of the treatment plan (given in Figure 8 or Table S2) evaluated using the
fluid model, appear to imply a very satisfactory treatment. The solid model becomes unreliable in
and around the CSF regions, vastly overestimating the temperature in the CSF regions, especially
the large fluid volume where the tumour has been excised. This is due to the lack of efficient heat
transport by perfusion and convection, which combine to result in a large heat accumulation. In this
region, the high-k models are substantially better approximations than the unadjusted solid model.
The T10 still tends to overestimate the CSF temperature, in particular in the target region, and only by a
modest amount; in general, overestimation of the T10 would be preferred over underestimation, as it is
related to the risk of healthy tissue damage through hot spots. It must be noted, however, that the
model used for post-operative is not completely realistic. For example, blood may mix with the CSF,
altering the dielectric and physical properties of the fluid. Additionally, the region around the excised
volume may deform, affecting flow patterns and the temperature distribution. Therefore, for clinical
practice, it is advisable to obtain a post-operative scan for post-operative hyperthermia treatment
planning, though the models in our study provide important basic insights in the difference between
the pre-operative and post-operative cases.
Increasing the value for keff increases the precision of the temperature simulation, in particular for
the CSF itself; naturally, this effect is more pronounced in the post-operative case. However, as the
median temperature is reduced, the median error changes from +0.1 ◦C to −0.4 ◦C. Increasing the value
for keff has a limited effect for keff/k & 20. This is in line with the results reported by Yuan et al. [58] for
the urinary bladder, who found that when using keff > 10 W/(m K) for the bladder, the temperature
difference between simulated and measured bladder temperatures tended to reach a plateau. A solid
foundation for a fixed choice of keff for the CSF requires a larger sample of cases simulated with
the fluid model. Another solution might involve adding a (small) heat sink term to the CSF model
analogous to the blood perfusion heat sink term in Pennes’ equation, which would serve to reduce
the extremely high temperatures erroneously predicted by the solid model(s). Results of bladder
studies show that such a term might improve the accuracy of the results [48]. Another alternative
might involve a temperature dependent or non-isotropic value for k, with a high value for k in the
direction perpendicular to the direction of gravity, and a higher value for k in de upward direction
than in the downward direction; such a non-isotropic k would be quite straightforward to implement
in a finite difference model. As the amount of heat transport by natural convection depends on the
actual temperature differences in the fluid, a more sophisticated keff model might implement a keff that
is proportional to temperature differences within the fluid volume, e.g., by relating keff to the local
temperature gradient.
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Uncertainties in the temperature dependency of the used parameters may have caused errors in the
prediction. There is little information in the literature about the relationship between temperature and
various physical parameters; this is most relevant for perfusion, but also for, e.g., electric conductivity
and permittivity. In this study, an increased perfusion value was used for muscle (which is hardly
present in and around the treatment area), but not for other tissue types, most notably not for grey and
white matter. Based on experiments with monkeys and dogs in the late eighties and early nineties,
cerebral perfusion is estimated to increase about 2.5-fold in healthy tissue and about 1.5-fold in tumour
tissue when the brain temperature is increased to hyperthermic temperatures [64–66]. Implementation
of such dynamic temperature dependent perfusion values would lead to relatively selective heating of
the tumour, and less risk of potential hot spots. This is also true for small CSF volumes which release
more of their heat to better perfused tissues, but the problem of avoiding CSF overheating remains for
larger volumes.
The Chalmers Hyperthermia Helmet is the only brain hyperthermia applicator designed specifically
for paediatric use. The fluid model simulations in this study show that the Chalmers Hyperthermia
Helmet is capable of obtaining an adequate tumour temperature, without inducing unacceptable hot
spots. The relatively large number of antennas (up to 16) and the wide frequency range (300–900 MHz)
of the antennas, allow for a high degree of spatial steering [38,54]. Hot spots may threaten to appear at
tissue interfaces with inhomogeneities in dielectric and thermal properties; in practice, these occur
mostly on CSF boundaries. The CSF may then serve to efficiently spread the excess heat over a larger
volume, reducing the risk of hot spots.
The results from this paper regarding the influence of CSF on the temperature distribution, apply
equally to various alternative hyperthermia applicators that are being or have been developed for
heating brain tumours, albeit that they are designed for adults, and not for paediatric applications.
A group in Berlin is developing a high field-strength MR-compatible applicator comprising a ring
of 16 bowtie antennas [67]. Their initial SAR simulation results look promising for relatively small
tumours, but they have not performed temperature simulations. However, temperature-based
planning, or at least temperature-based plan verification is preferable, in our view, as there is no
direct correlation between SAR and temperature between different tissue types. A 72-channel
915-MHz system (HYPER-crown) is currently being developed specifically for brain tumours by a
commercial party [68], similar to the existing HYPER-collar [69]. Treatment planning for these devices
is mostly SAR-based [69,70], but treatment monitoring and treatment evaluation may use temperature
simulations. Temperature simulation data for brain tumours are not available, but temperature
simulations for head and neck sarcomas for treated with the HYPER-collar showed an error of about
2 ◦C relative to measurements during treatment using patient-group optimised parameters [71,72].
The discussed brain hyperthermia applicators (including the Chalmers Hyperthermia Helmet)
are all MR-compatible, so that, in principle, temperature may be monitored during treatment using MR
thermometry. However, especially in a post-operative scenario with a large fluid-filled pocket, these
measurements may be unreliable in and around the CSF-filled pocket due to motion artefacts; this is
similar to MR-thermometry in and around the urinary bladder [73], for which an MR thermometry
accuracy of 1.86 ± 1.20 ◦C has been reported [74]. Therefore, additional forms of treatment guidance
would still be needed, such as numerical temperature simulation; if possible, supplemented with,
preferably invasive, thermometry. If MR-guidance is used, SAR and temperature simulations may
be further improved by obtaining patient-specific (and possibly temperature dependent) dielectric
parameters [75].
Fluid dynamics modelling is also of crucial importance for other brain heating techniques, such as
magnetic nanoparticles. The first clinical results of magnetic nanoparticle heating for glioblastoma
have been reported, which showed that controlled heating is quite challenging [20]. Although aiming
for hyperthermic temperatures of 43 ◦C, ablative temperatures of up to 82 ◦C have been recorded
during treatment. If these nanoparticles are transported by the CSF, this adds an additional importance
to model fluid behaviour in order to track and/or predict the distribution of these nanoparticles.
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In the end, the exact requirements on the heating pattern and the accuracy with which the treatment
can be predicted or reconstructed, depend primarily on the relevant hyperthermia mechanism, which in
turn may depend on the primary treatment modality: radiotherapy and/or chemotherapy. For example,
for certain chemotherapy applications, it may be particularly important to have accurate knowledge
whether sufficiently high temperatures have been reached to open the blood brain barrier. When
drugs are delivered using thermosensitive liposomes (nanocarriers that release their payload above a
certain activation temperature), it is especially important to know the volume where the activation
temperature of the liposomes has been obtained. In the case of radiotherapy, it may both be relevant
to know whether the temperature was adequate to inhibit fast DNA damage repair, and to know
the complete thermal dose for slow DNA damage repair. Regardless of treatment modality, accurate
knowledge of presence or absence of hot spots in healthy tissue is always important.
Using the current set-up, simulating the fluid simulations took more than 15 min (pre-operative)
or almost 30 min (post-operative) of real time for each second of simulation time. Evidently, this
makes the fluid dynamics model in its current form unpractical for clinical use. A lower resolution
would greatly speed up the computations, but this may negatively affect the accuracy in both the
spatial and temperature domains. In a well-controlled phantom experiment, we showed that the fluid
solver remains accurate when using 2.5 mm-based cells instead of 1 mm-based cells [47], but this may
result in losing smaller CSF canals. A possible solution might be to use a high resolution around the
tumour location and in regions with a high SAR. As for clinical applications steady state temperatures
are of central importance, a steady state solver (e.g., based on the SIMPLE algorithm [57]) might be
more efficient. Temperature-based optimisation will, most likely, remain unfeasible, but the increase
in speed may be sufficient for treatment plan validation. Given the current practical limitations on
computation times and the relatively good approximations of the high-k model, an acceptable workflow
might comprise doing the amplitude and phase optimisation using a computationally efficient high-k
model (with keff/k equal to about 10–20), possibly with relaxed constraints on the temperature in
the CSF. Preferably, such a plan should be validated with a final check using a (steady-state) fluid
dynamics model.
5. Conclusions
Heating the brain is a promising (adjuvant) treatment option, but also challenging. For estimating
thermal dose parameters for the tumour, physically correct fluid modelling may not be required.
For healthy tissue, however, not taking fluid behaviour into account may lead to erroneous predictions
of severe hot spots. Unfortunately, the applied thermophysical fluid model is, in its current state, not
fast enough for routine clinical use. As an intermediate solution, a temperature that is accurate to
within about 1 ◦C may be obtained for tissues (excluding CSF itself) by modelling CSF as a special
solid with an increased effective thermal conductivity; this may be sufficiently accurate for clinical
use, provided stringent safety margins are maintained. The optimal value for the effective thermal
conductivity depends on the individual case, but a roughly 10–20-fold increase appears to best balance
the different effects of convective heat transport on the temperature distribution.
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Table S1. Thermal parameters for the analysis of a single treatment plan (ergo the same SAR-distribution),
according to three different models; results for the pre-operative case. Treatment target evaluation parameters T90,
T50 and T10 are given, i.e., the temperature exceeded by, respectively, 90, 50 and 10% of the volume (temperatures
in the range 42–43 ◦C are generally considered clinically optimal temperatures). For the healthy tissue, the volume
exceeding, respectively, 41, 42 and 43 ◦C is given (lower volumes are clinically preferred). Total volume: white
matter = 124.669 mL; grey matter = 1006.547 mL; CSF = 339.982 mL; tumour = 92.031 mL. Table S2. Thermal
parameters for the analysis of a single treatment plan (ergo the same SAR-distribution), according to three different
models; results for the post-operative case. Treatment target evaluation parameters T90, T50 and T10 are given, i.e.,
the temperature exceeded by, respectively, 90, 50 and 10% of the volume (temperatures in the range 42–43 ◦C are
generally considered clinically optimal temperatures). For the healthy tissue, the volume exceeding, respectively,
41, 42 and 43 ◦C is given (lower volumes are clinically preferred). Total volume: white matter = 124.669 mL; grey
matter = 1006.547 mL; CSF = 447.709 mL.
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